Purpose {#S0001}
=======

Uterine cervix cancer has a high incidence in developing countries and, despite the screening programs, diagnosis in an advanced stage is still common. In Latin America, incidence rates range from 20 to 80 per 100 000 women per year \[[@CIT0001]\], however, screening protocols are not available for all women, resulting in a small impact effect in mortality reduction. In Brazil, the National Cancer Institute estimates an incidence of 16,340 new cervix cancer cases in 2016 with an estimated risk of 15.85/100 000 women \[[@CIT0002]\]. Fortunately, both prophylaxis and management of patients with uterine cervix cancer have improved in recent years. This evolution has been mostly triggered by the new development of targeted systemic therapies and by advances in tridimensional (3D) brachytherapy.

Compatible computed tomography (CT) and magnetic resonance (MRI) tandem, ring, and ovoids have enabled the acquisition of 3D pelvic images with the applicators placed in the treatment position, allowing a good perception of tumor volume and its relation to the applicators. To help clinicians move forward and standardize treatments in this new technique, guidelines in image-guided brachytherapy (IGBT) have been written \[[@CIT0003]\]. It was demonstrated that tumor coverage with the conventional two-dimensional (2D) plan, based on semi-orthogonal radiographs, was suboptimal, especially for large lesions, and IGBT could achieve a better tumor coverage and reduce dose to normal tissue \[[@CIT0004]\]. In fact, great outcomes were reported by the Vienna and Aarhus groups \[[@CIT0005], [@CIT0006], [@CIT0007]\], suggesting the superiority of IGBT against conventional brachytherapy. Better toxicity profile, higher local control, and specific disease-free survival were also observed in these reports. Public health in developing countries has limited resources, and implementation of a new technology should be rationalized and confronted with its related costs. Despite the benefits associated with IGBT in cervix carcinoma treatment, MRI availability and costs in each fraction of brachytherapy plus staff time consumed to perform the treatment represent some of the limiting factors. Thus, there is a need for further progress with regards to patient stratification and procedure evaluation to leverage a more positive cost-effective ratio. In this scenario, the Vienna group \[[@CIT0005], [@CIT0006]\] has reported that patients who benefit the most from IGBT are those with locally advanced disease, particularly women with tumors larger than 5 cm.

In 2010, our institution started a study for implementation of 3D IGBT. One of the goals was to optimize the resources for the procedure. In preparation to start an IGBT program, a tumor volume regression evaluation was done.

This study aimed to evaluate tumor regression kinetics pattern in patients with cervical cancer treated with chemoradiation.

Material and methods {#S0002}
====================

This study was approved by the institutional ethical committee (Comissão de Ética para Análise de Projetos de Pesquisa -- CAPPesq da Diretoria Clínica do HCFMUSP) and registered as: CAPPesq n° 1100/08. Before the beginning of the study, all patients had signed an informed consent.

From February 2010 to December 2011, fourteen patients with confirmed histological diagnosis of cervix squamous cell or adenocarcinoma were enrolled. Good performance status (ECOG \< 3), a pelvic MRI at diagnosis, and FIGO stages IB to IIIB were required for inclusion in this study.

Patients were recruited sequentially and treated in accordance to the institutional protocol, which comprises additional local staging with pelvic MRI, pelvic external beam radiation therapy (EBRT) with concomitant weekly cisplatin-based chemotherapy, and two-dimensional (2D) intracavitary high-dose-rate brachytherapy (HDRB). Pelvic EBRT was performed with 6 or 15 MV photons, in 25 fractions of 1.8 Gy each (45 Gy total dose) with a 4-field conformal box technique. Patients with involved parametria received a 14 Gy boost in 7 fractions with opposed anterior-posterior/posterior-anterior fields and central shielding. High-dose-rate brachytherapy was delivered during EBRT once a week in four fractions of 7 or 7.5 Gy, prescribed at Manchester point A (7.5 Gy was prescribed for stage III patients). Dose constraints at ICRU 38 bladder and rectal points were limited to 65% of point A dose. In our practice, patients are routinely reassessed with gynecological exams after the second week of EBRT in order to evaluate local anatomy/geometry for brachytherapy. If brachytherapy is not performed, patients continue through weekly gynecological exams until proper geometry is achieved. Usually, these patients start brachytherapy after the end of the pelvic irradiation, and fractions are delivered twice a week in order to finish the whole treatment in less than 8 weeks. Chemotherapy consisted of weekly cisplatin 40 mg/m^2^ up to six cycles given concomitantly to radiotherapy. No chemotherapy or EBRT were allowed on the days of brachytherapy.

The brachytherapy protocol for implementation of 3D IGBT followed exactly the same schedule, except for the performance of MRI in the first and third HDRB fractions, and CT scans in the second and fourth HDRB fractions. Local anesthesia and conscious sedation were used for cervix dilation and placement of the CT-MR compatible tandem-ring applicator (Nucletron^®^, an Elekta Company, Sweden), under ultrasound guidance. All patients were treated with standard 2D technique using semi-orthogonal pelvic radiographs. Plato^®^ version 14.1 and subsequently Oncentra Masterplan^®^ version 4.1 (Nucletron^®^, an Elekta Company, Sweden) were the planning systems used for calculations. Magnetic resonance images, both at diagnosis and at brachytherapy, were performed with a 1.5 Tesla GE Signa HDxt scanner (GE Healthcare, Chalfont St. Giles, UK \[a unit of General Electric Company\] ^®^), with 3 mm slice thickness. The assessment of the target extension in all planes was performed in para-transverse, para-coronal, and sagittal planes oriented according to the uterine axis or the applicator, in T2-weighted FSE sequences, following the GEC-ESTRO recommendations \[[@CIT0008]\]. In order to avoid bladder volume variations, all patients had their bladder emptied and subsequently filled with 50 ml of saline solution before each image acquisition and treatment procedures.

Tumor (gross tumor volume \[GTV\], high-risk clinical target volume \[HR-CTV\], intermediate-risk clinical target volume \[IR-CTV\]) and organs at risk \[OAR\] -- bladder, rectum and sigmoid) volumes delineation were performed on MRI studies using T2-weighted images, in accordance with the GEC-ESTRO recommendations \[[@CIT0008]\]. Three independent senior radiation oncologists and one pelvic expert radiologist participated in volume delineation of each MRI image. Definitive volume was defined by agreement of at least two radiation oncologists and the radiologist.

Tumor volume was defined by slice-by-slice MRI contouring (VC) and also estimated by the ellipsoid formula (VE), which, is the product of the three largest diameters in three different plans (axial, sagittal, and coronal) of the MRI multiplied by π/6, as already used by others \[[@CIT0009]\].

VC and VE were calculated on MRI at diagnosis (D) and, in the first (B1) and third (B3) brachytherapy fractions. The kinetic of tumor reduction was then evaluated for each patient. Computed tomography images were not used for the matter of this report.

Descriptive analysis was performed to describe frequencies and interquartile intervals. Since data distribution was not normal, non-parametric tests were used for comparisons. Friedman test and Wilcoxon sign rank test evaluated tumor volumes regression. Spearman correlation test evaluated VC and VE. Statistical significance was set at 5% (*p* \< 0.05).

Results {#S0003}
=======

Patients characteristics {#S20004}
------------------------

One out of fourteen patients enrolled in this protocol was excluded due to psychiatric disorder, which disabled MRI to be performed during brachytherapy. Thus, thirteen women with 39 MRIs were the object of this study. Patients median age was 46 years (range 31 to 76 years) and all of them had ECOG performance status equal to zero. Nine patients had squamous cell histology and the others adenocarcinoma. Two patients presented FIGO stage IB, one stage IIA, nine were IIB, and one IIIB. Among IIB cases, two presented with enlarged pelvic lymph node considered to be positive.

Treatment {#S20005}
---------

Radiotherapy started with a median delay of 49 days (range 10 to 102 days) from the date of diagnostic pelvic MRI, and the median start time between EBRT and the first brachytherapy fraction was 36 days (range 23 to 95 days). All patients received six cycles of cisplatin, except for one, who received five cycles. The entire oncological treatment was completed within a median time of 60 days (range: 47 to 83 days). Three patients presented more extended total treatment time mainly due to interruptions related to hematological toxicity of the chemoradiation schedule. Seven patients initiated HDRB between the third and fifth week of EBRT and six after 45 Gy EBRT to the pelvis.

All HDRB fractions were performed with tandem and ring applicator using the rectal retractor. One out of 13 patients had the ring diameter reduced from 34 mm to 30 mm along treatment; two patients had the tandem length shortened from 60 mm to 40 mm, and in one patient, a different applicator angle was used along brachytherapy fractions.

Volumes analysis {#S20006}
----------------

[Figure 1](#F0001){ref-type="fig"} shows tumor volume regression throughout oncological treatment. Most of the gross tumor volume reduction occurred from the diagnostic MRI to the first brachytherapy fraction ([Figure 2](#F0002){ref-type="fig"}).

![Gross tumor volumes (GTV) in each patient calculated by the ellipsoid formula (VE) and slice-by-slice contouring (VC) at magnetic resonance imaging at diagnosis (D), first (B1), and third (B3) brachytherapy fractions](JCB-8-28140-g001){#F0001}

![Magnetic resonance (T2-weighted images, sagittal view) of patient \#3 that presented good response (white arrow). D -- at diagnosis, B1 -- at first brachytherapy fraction, and B3 -- at third brachytherapy fraction, respectively](JCB-8-28140-g002){#F0002}

[Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} compare tumor volumes estimated by the ellipsoid formula (VE) and calculated by MRI contouring (VC) in three different moments: D, B1, and B3. A mean absolute volume reduction of approximately 16 cc was observed between diagnosis and the first brachytherapy fraction by both calculation methods. This volume reduction represented 61.9% and 75.2% of the diagnostic GTV, when measured by VE and VC, respectively. We compared tumor kinetics' of the seven patients in whom brachytherapy was started before the end of EBRT with the other six where HDRB started after completion of EBRT (45 Gy). VE and VC at diagnosis were similar in both groups (*p* = 0.173 and 0.686, respectively), as the tumor regression pattern evaluated by VE and VC at B1 (*p* = 0.116 and 0.753, respectively).

###### 

Ellipsoid formula (VE) estimated volume along treatment: at diagnosis (GTV~D~), first (GTV~B1~), and third (GTV~B3~) brachytherapy fractions

  VE        Median (IQ) (cc)    Shrinkage (%)   *p*[\*](#TF0001){ref-type="table-fn"}   *p*[\#](#TF0002){ref-type="table-fn"}
  --------- ------------------- --------------- --------------------------------------- ---------------------------------------
  GTV~D~    25.5 (17.4-116.8)   61.9            0.001                                   0.0001
  GTV~B1~   9.7 (1.3-18.0)                                                              
  GTV~B1~   9.7 (1.3-18.0)      54.7            0.008                                   
  GTV~b3~   4.4 (0.05-16.6)                                                             
  GTV~d~    25.5 (17.4-116.8)   82.7            0.005                                   
  GTV~b3~   4.4 (0.05-16.6)                                                             

Wilcoxon signed rank test

Friedman test

IIQ -- interquartile range

###### 

Slice-by-slice delineation volume (VC) along treatment: at diagnosis (GTV~D~), first (GTV~B1~), and third (GTV~B3~) brachytherapy fractions

  VC        Median (IQ) (cc)    Shrinkage (%)   *p*[\*](#TF0003){ref-type="table-fn"}   *p*[\#](#TF0004){ref-type="table-fn"}
  --------- ------------------- --------------- --------------------------------------- ---------------------------------------
  GTV~d~    21.0 (11.3-103.9)   75.2            0.001                                   0.0001
  GTV~b1~   5.2 (0.5-18.9)                                                              
  GTV~b1~   5.2 (0.5-18.9)      55.8            0.008                                   
  GTV~b3~   2.3 (0-14.5)                                                                
  GTV~d~    21.0 (11.3-103.9)   89.0            0.005                                   
  GTV~b3~   2.3 (0-14.5)                                                                

Wilcoxon signed rank test

Spearman\'s correlation test

IQ -- interquartile range

Mean overall tumor shrinkage, evaluated by VE and VC, from the diagnostic MRI to third brachytherapy fraction was 82.7% and 89.0%, respectively. Thus, only a modest reduction of 15-20% of the GTV volume was seen between the first and third HDRB fractions. Again, no statistically significant differences were observed in tumor kinetics' when patients were evaluated according to the dose of EBRT received at B3.

No significant correlation was found between VE and VC at the diagnostic MRI. VE calculation overestimated the contoured volume. However, VE and VC were statistically significant correlated in both B1 and B3, with a higher correlation index observed in smaller tumor volumes ([Figure 3](#F0003){ref-type="fig"}, [Table 3](#T0003){ref-type="table"}).

![Tumor median volumes calculated by ellipsoid formula (VE) and slice-by-slice delineation (VC) at magnetic resonance imaging diagnosis (D), first (B1), and third (B3) brachytherapy fractions](JCB-8-28140-g003){#F0003}

###### 

Tumor volumes comparisons calculated by VE and VC at diagnosis (GTV~D~), first (GTV~B1~), and third (GTV~B3~) brachytherapy fractions

  Volume                        Median (IQ) (cc)    Range (cc)   *p*[\*](#TF0005){ref-type="table-fn"}   rho[\#](#TF0006){ref-type="table-fn"}   *p*[\#](#TF0006){ref-type="table-fn"}
  --------- ------------------- ------------------- ------------ --------------------------------------- --------------------------------------- ---------------------------------------
  GTV~d~    VE                  25.5 (17.4-116.8)   12.6-184.2   0.023                                   0.505                                   0.078
  VC        21.0 (11.3-103.9)   7.6-164.8                                                                                                        
  GTV~b1~   VE                  9.7 (1.3-18.0)      0.5-86.3     0.650                                   0.604                                   0.029
  VC        5.2 (0.5-18.9)      0.0-151.5                                                                                                        
  GTV~b3~   VE                  4.4 (0.05-16.6)     0.0-38.2     0.678                                   0.726                                   0.017
  VC        2.3 (0-14.5)        0-97.7                                                                                                           

Wilcoxon signed rank test

Spearman\'s correlation test

IQ -- interquartile range, VE -- ellipsoid formula, VC -- slice-by-slice delineation volume

High-risk clinical target volume in B1 and B3 were also evaluated. VC presented similar volumes in B1 and B3, with a median volume estimated as 21.4 cc (7-151 cc) and 21.6 cc (11-97 cc), respectively. Both volumes were highly correlated (rho = 0.891/*p* = 0.001; Spearman correlation test).

Discussion {#S0007}
==========

Brachytherapy is fundamental in the treatment of advanced uterine cervix cancer because improves overall survival \[[@CIT0010]\]. Image-guided brachytherapy is a recent evolution from 2D brachytherapy and allows clinicians to optimize treatment to a visible and measurable gross tumor volume. This is particularly useful when we are faced with large tumors, as often diagnosed in developing countries \[[@CIT0011]\]. Thus, dose prescription and isodose shaping can be individualized in accordance to specific tumor, the cervix and suspicious extra-cervical residual tissues while taking the initial tumor shape and size into account, and OAR anatomy. As expected, toxicity profile related to this technique is milder in comparison to that achieved with 2D brachytherapy \[[@CIT0012], [@CIT0013], [@CIT0014]\]. Moreover, absolute local control can be approximately 20% higher than published results using 2D technique in the literature resulting in an absolute 3-year cancer specific survival benefit of 13 to 30% in patients with tumors larger than 5 cm \[[@CIT0006], [@CIT0012], [@CIT0013]\].

In order to perform IGBT, a 3D pelvic image acquisition with the applicators in place is necessary. Both CT and MRI are useful in this setting but MRI provides a better soft tissue contrast and is superior in gross tumor volume definition \[[@CIT0015], [@CIT0016]\]. However, MRI is more expensive than CT and its image acquisition is longer, thus limiting its use in developing countries where cervix cancer has a high incidence.

In the present study, tumor kinetics' along cancer treatment was evaluated by serial MRIs. Around 70% tumor volume reduction was achieved from diagnosis to the first HDRB fraction, which is in accordance to others findings \[[@CIT0017]\]. Considering that in the present patient cohort there was a median delay of 49 days from the diagnostic MRI to the initiation of brachytherapy, it is possible that the relative volume reduction between tumor volume prior to EBRT and the first fraction of brachytherapy would be even larger than 70%. This delay may represent a limitation of our study. Nevertheless, this important volume reduction in the first weeks of EBRT suggests that IGBT could start, at least after the third week of EBRT, since after this period, a substantial regression of tumor\'s volume is not expected. One may argue that a maximum tumor regression is observed at the end of EBRT, and thus, IGBT should be performed at this point, making our analysis irrelevant. However, in this scenario, brachytherapy would preferably be delivered in two fractions per week in order to avoid an extended total treatment time over 56 days. This may represent a burden in very busy departments like ours, justifying why efforts are done to start brachytherapy during EBRT. Nevertheless, even in this small cohort of patients, median overall treatment time was 60 days, slightly higher than the desirable.

Most patients were submitted to brachytherapy after the third week of EBRT according to clinical evaluation by weekly gynecological exams. This was compatible with the volume regression observed by MRI. For smaller tumors, volume variation was obviously smaller, and brachytherapy was performed earlier with no major impact in HR-CTV delineation, since this CTV comprehends the entire cervix, harboring or not the disease, and treatment volumes may not change significantly between HDR fractions \[[@CIT0003]\]. This may be the case of most patients in this study, in which a relatively small disease burden was found at diagnosis (median GTVD by VC = 21 cc, [Table 2](#T0002){ref-type="table"}). For larger tumors where tumor regression has a major impact in volume delineation, postponing the procedure would be more useful. Thus, weekly gynecological evaluation in our experience was helpful to manage the timing for the first brachytherapy fraction in this setting. This represents one of the highlights of our study.

On the other hand, in this group of patients, while performing images enabling 3D procedures, HDRB was delivered with 2D based calculation. This is another limitation of our study, since no dose-volume parameters were considered in this analysis. Nevertheless, during this period, it was possible to establish a new routine for applicator placement and fixation (with only local anesthesia and sedation), to establish a method for transportation of the patient to the imaging rooms, and to training of tumor volumes contouring in MRI, as well as develop all the process for implementation of an IGBT programme \[[@CIT0018]\]. The tumor shrinking kinetics approach was used to establish better timing for the procedure and to possibly save some resources. Performing MRI in a timely manner may allow its use only in the first IGBT fraction, followed by CT based insertions in the subsequent fractions, as already proposed by others \[[@CIT0015], [@CIT0019]\]. Since CT contoured volumes are known to overestimate the target \[[@CIT0015]\], tumor regression evaluation may be helpful to achieve more accurate delivery of CT-based IGBT fractions. Possibly, following this strategy, a good ratio between MRI benefits and costs could be found and this resource be more often allocated for treatment of cervical cancer patients in developing countries.

The main objective of this study was the evaluation of the tumor shrinkage during treatment. In addition, the feasibility of the procedure was evaluated for further implementation of the method in the institution. No sample size was calculated upfront, neither a maximum time between the diagnosis MRI and the initiation of EBRT or HDRB was required. We are aware that the small number of patients and the variation of time elapsed since diagnosis MRI to treatment also represent limitations of this study. On the other hand, our results may better reflect obstacles and difficulties to implement the technology at our institution, in a group of patients treated according to our daily routine. But, even with these limitations, our results were in agreement with others that looked at tumor shrinkage during irradiation \[[@CIT0017], [@CIT0020], [@CIT0021]\]. In these studies, the effects of EBRT alone or brachytherapy on tumor shrinkage were evaluated. In our study, tumor regression was evaluated in a different treatment schedule with HDRB performed during chemoradiation. Brachytherapy when performed during chemoradiation may present an even higher tumor regression and the influence of this combination may be explored in further studies.

A parallel result of this study was the comparison between the different methods of volume evaluation throughout treatment. Not surprisingly, the ellipsoid formula overestimated the gross tumor volume on the staging MRI. As expected, large tumor volumes with irregular shapes are not well estimated by VE that takes into consideration spheroid shapes using only three planes coordinates. As tumor shrinks, the estimated VE better correlates with VC. These findings are in accordance with Mayr *et al*. \[[@CIT0009]\], and may indicate that the results of Dimopoulos *et al*. \[[@CIT0017]\], based on the ellipsoid formula, may either under or overestimate tumor regression. Despite these differences between tumor volumes measured by VE and VC due to limitations of the ellipsoid formula, both methods were consistent and presented a similar pattern of tumor volume reduction along treatment as shown in [Figure 2](#F0002){ref-type="fig"}. In addition, the volumes were defined by a consensus of at least three experienced professionals among radiologists and radiation oncologists, which gives reliability to the measures performed, and prevents delineation uncertainties \[[@CIT0022]\]. These findings should be validated with a larger number of patients.

Not in the scope of this study but worth to comment, tumor regression during treatment may also be used as a prognostic factor \[[@CIT0009], [@CIT0023], [@CIT0024], [@CIT0025]\], and as a very useful tool in order to pre-plan the brachytherapy procedure -- intracavitary only or associated with interstitial implant \[[@CIT0026]\].

The level of MRI utilization in IGBT depends on the infrastructural capabilities of individual centers, ranging from no use at all to repetitive imaging during EBRT and each IGBT fraction \[[@CIT0027]\]. Despite the large number of uterine cervix cancer cases at our institution, only two patients per month could be recruited due to the overloading of the MRI agenda, which reflects the difficulties faced by our country, even in a reference center. For this same reason, studies looking at resource\'s optimization are warranted and welcome in this context.

The benefits of the better use of technical resources come with the charge of personnel training and the more time-consuming of the whole treatment process. The later represents a limitation for the routine use of 3D IGBT in developing countries where radiation oncology departments are busy, usually with waiting lists, and with limited human and technical resources \[[@CIT0028]\]. Currently, our department is able to perform only one case per month (one fraction/week) of intracavitary 3D IGBT due to logistical issues. No interstitial implants are being performed in this context yet. Thus, understanding which patients would benefit the most from these technique is desirable, until it becomes possible to offer this technology for all patients. The results of this study helped us to establish a routine in the department, even for 2D brachytherapy treatments, in which patients with indication of HDRB for cervix cancer should start the procedure after the third week of treatment. This understanding is important to build a resource-saving strategy and successfully allocate limited available funds in undeveloped countries. MRI-guided brachytherapy in the first fraction followed by CT-based brachytherapy for the subsequent fractions may lead to more accurate treatment, if steep tumor volume reduction is waited to occur.

Conclusions {#S0008}
===========

Most expressive tumor shrinkage occurs during the first three weeks of chemoradiation. Clinical evaluation by gynecological exams helped to determine the optimal time for brachytherapy and were in accordance with imaging exams. This finding may help in the decision making process of 3D-IGBT implementation.
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